Tech Company Financing Transactions
Minoryx Therapeutics Funding Round
Minoryx Therapeutics closed a $22.1 million Series A venture capital round on 10/15/2015. Investors included Ysios Capital, Chiesi Ventures and IDinvest Partners.
Transaction Overview
Company Name
Announced On
10/15/2015
Transaction Type
Venture Equity
Amount
$22,100,000
Round
Series A
Investors
Proceeds Purpose
The funds raised will be used to complete the team, especially in R&D, to move lead project MIN-102 to clinical validation and to further develop a pipeline of non-competitive pharmacological chaperones identified through the company's innovative proprietary platform, SEE-Tx.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Av. Ernest Lluch 32 TCM3
Barcelona, 08302
Spain
Barcelona, 08302
Spain
Phone
Website
Email Address
Overview
We are currently focused on Inborn Errors of Metabolism, a group of rare diseases of genetic origin with high unmet medical need. Such diseases are life threatening and highly debilitating, usually with neurological manifestations and affect most severely the pediatric population.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marc Martinell
Chief Medical Officer
Uwe Meya
Chief Operating Officer
Didier Le Normand
VP - Operations
Sílvia Pascual
VP - Regulatory Affairs
María Pascual
Browse more venture capital transactions:
Prev: 10/15/2015: Playlab venture capital transaction
Next: 10/15/2015: Clustree venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs